{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:19:08Z","timestamp":1791274748988,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40119-025-00438-0","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T09:23:30Z","timestamp":1763976210000},"page":"671-685","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-World Adherence and Effectiveness of Inclisiran in Lowering LDL-C: Results from 1 Year of Follow-Up"],"prefix":"10.1007","volume":"14","author":[{"given":"Christie M.","family":"Ballantyne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9135-096X","authenticated-orcid":false,"given":"Lucinda J.","family":"Van Anglen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce J.","family":"Iteld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"Serota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"McElligott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9795-8837","authenticated-orcid":false,"given":"Tyler J.","family":"Varisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"25","key":"438_CR1","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","volume":"82","author":"GA Mensah","year":"2023","unstructured":"Mensah GA, Fuster V, Murray CJL, et al. Global burden of cardiovascular diseases and risks, 1990\u20132022. J Am Coll Cardiol. 2023;82(25):2350\u2013473. https:\/\/doi.org\/10.1016\/j.jacc.2023.11.007.","journal-title":"J Am Coll Cardiol"},{"key":"438_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahjo.2022.100201","volume":"21","author":"CJ Alanaeme","year":"2022","unstructured":"Alanaeme CJ, Bittner V, Brown TM, et al. Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA\/ACC multi-society cholesterol guideline. Am Heart J Plus. 2022;21:100201. https:\/\/doi.org\/10.1016\/j.ahjo.2022.100201.","journal-title":"Am Heart J Plus"},{"issue":"32","key":"438_CR3","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144.","journal-title":"Eur Heart J"},{"issue":"9753","key":"438_CR4","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/s0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381. https:\/\/doi.org\/10.1016\/s0140-6736(10)61350-5.","journal-title":"Lancet"},{"issue":"24","key":"438_CR5","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285-350. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.003.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"438_CR6","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1097\/01.hjr.0000189805.76482.6e","volume":"13","author":"G Assmann","year":"2006","unstructured":"Assmann G, Benecke H, Neiss A, Cullen P, Schulte H, Bestehorn K. Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians\u2019 Experience and Evaluation). Eur J Cardiovasc Prev Rehabil. 2006;13(5):776\u201383. https:\/\/doi.org\/10.1097\/01.hjr.0000189805.76482.6e.","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"issue":"5","key":"438_CR7","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00392-017-1193-z","volume":"107","author":"KM Fox","year":"2018","unstructured":"Fox KM, Tai MH, Kostev K, Hatz M, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2018;107(5):380\u20138. https:\/\/doi.org\/10.1007\/s00392-017-1193-z.","journal-title":"Clin Res Cardiol"},{"key":"438_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2017.11.020","volume":"268","author":"W M\u00e4rz","year":"2018","unstructured":"M\u00e4rz W, Dippel FW, Theobald K, Gorcyca K, Iorga \u015eR, Ansell D. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: real-world evidence from Germany. Atherosclerosis. 2018;268:99\u2013107. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.11.020.","journal-title":"Atherosclerosis"},{"key":"438_CR9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ijcard.2016.09.075","volume":"225","author":"M Banach","year":"2016","unstructured":"Banach M, Stulc T, Dent R, Toth PP. Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement. Int J Cardiol. 2016;225:184\u201396. https:\/\/doi.org\/10.1016\/j.ijcard.2016.09.075.","journal-title":"Int J Cardiol"},{"issue":"9","key":"438_CR10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00392-016-0991-z","volume":"105","author":"U Laufs","year":"2016","unstructured":"Laufs U, Karmann B, Pittrow D. Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk. Clin Res Cardiol. 2016;105(9):783\u201390. https:\/\/doi.org\/10.1007\/s00392-016-0991-z.","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"438_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"issue":"9","key":"438_CR12","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/jamacardio.2017.2289","volume":"2","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Khan I, Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJ. Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2(9):959\u201366. https:\/\/doi.org\/10.1001\/jamacardio.2017.2289.","journal-title":"JAMA Cardiol"},{"key":"438_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ahj.2024.06.012","volume":"279","author":"AM Navar","year":"2025","unstructured":"Navar AM, Shah NP, Shrader P, et al. Achievement of LDL-C <55 mg\/dl among US adults: findings from the cvMOBIUS2 registry. Am Heart J. 2025;279:107\u201317. https:\/\/doi.org\/10.1016\/j.ahj.2024.06.012.","journal-title":"Am Heart J"},{"issue":"8","key":"438_CR14","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1080\/00325481.2022.2117498","volume":"134","author":"J Underberg","year":"2022","unstructured":"Underberg J, Toth PP, Rodriguez F. LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals. Postgrad Med. 2022;134(8):752\u201362. https:\/\/doi.org\/10.1080\/00325481.2022.2117498.","journal-title":"Postgrad Med"},{"issue":"22","key":"438_CR15","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"issue":"12","key":"438_CR16","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s40265-016-0613-0","volume":"76","author":"S Kr\u00e4henb\u00fchl","year":"2016","unstructured":"Kr\u00e4henb\u00fchl S, Pavik-Mezzour I, von Eckardstein A. Unmet needs in LDL-C lowering: when statins won\u2019t do! Drugs. 2016;76(12):1175\u201390. https:\/\/doi.org\/10.1007\/s40265-016-0613-0.","journal-title":"Drugs"},{"issue":"5","key":"438_CR17","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jacl.2019.07.005","volume":"13","author":"L Annemans","year":"2019","unstructured":"Annemans L, Stock JK, Chapman MJ. PCSK9 inhibition, atherosclerotic cardiovascular disease, and health economics: challenges at the crossroads. J Clin Lipidol. 2019;13(5):714\u201320. https:\/\/doi.org\/10.1016\/j.jacl.2019.07.005.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"438_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jacl.2020.11.004","volume":"15","author":"B Zafrir","year":"2021","unstructured":"Zafrir B, Egbaria A, Stein N, Elis A, Saliba W. PCSK9 inhibition in clinical practice: treatment patterns and attainment of lipid goals in a large health maintenance organization. J Clin Lipidol. 2021;15(1):202\u201311.e2. https:\/\/doi.org\/10.1016\/j.jacl.2020.11.004.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"438_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.5603\/CJ.a2017.0137","volume":"25","author":"M Saborowski","year":"2018","unstructured":"Saborowski M, D\u00f6lle M, Manns MP, Leitolf H, Zender S. Lipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: effectiveness, therapy adherence and safety in a real world cohort. Cardiol J. 2018;25(1):32\u201341. https:\/\/doi.org\/10.5603\/CJ.a2017.0137.","journal-title":"Cardiol J"},{"key":"438_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2147\/vhrm.S180496","volume":"14","author":"DM Hines","year":"2018","unstructured":"Hines DM, Rane P, Patel J, Harrison DJ, Wade RL. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors. Vasc Health Risk Manag. 2018;14:409\u201318. https:\/\/doi.org\/10.2147\/vhrm.S180496.","journal-title":"Vasc Health Risk Manag"},{"issue":"1","key":"438_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1056\/NEJMp1614154","volume":"376","author":"A Khvorova","year":"2017","unstructured":"Khvorova A. Oligonucleotide therapeutics\u2014a new class of cholesterol-lowering drugs. N Engl J Med. 2017;376(1):4\u20137. https:\/\/doi.org\/10.1056\/NEJMp1614154.","journal-title":"N Engl J Med"},{"key":"438_CR22","unstructured":"Novartis Pharmaceuticals Corporation. LEQVIO\u00ae (inclisiran). Highlights of prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/214012s016lbl.pdf. Accessed Sept 30, 2025."},{"issue":"16","key":"438_CR23","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/nejmoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319. https:\/\/doi.org\/10.1056\/nejmoa1912387.","journal-title":"N Engl J Med"},{"issue":"16","key":"438_CR24","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1913805.","journal-title":"N Engl J Med"},{"issue":"6","key":"438_CR25","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40256-024-00665-1","volume":"24","author":"BD Bertolet","year":"2024","unstructured":"Bertolet BD, Cabral KP, Sullenberger L, McAlister JL, Sandroni T, Patel DS. Clinical considerations for healthcare provider-administered lipid-lowering medications. Am J Cardiovasc Drugs. 2024;24(6):729\u201341. https:\/\/doi.org\/10.1007\/s40256-024-00665-1.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"6","key":"438_CR26","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.jacl.2023.09.005","volume":"17","author":"JWCM Mulder","year":"2023","unstructured":"Mulder JWCM, Galema-Boers AMH, Roeters van Lennep JE. First clinical experiences with inclisiran in a real-world setting. J Clin Lipidol. 2023;17(6):818\u201327. https:\/\/doi.org\/10.1016\/j.jacl.2023.09.005.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"438_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2022-002184","volume":"9","author":"P Padam","year":"2022","unstructured":"Padam P, Barton L, Wilson S, et al. Lipid lowering with inclisiran: a real-world single-centre experience. Open Heart. 2022;9(2):e002184. https:\/\/doi.org\/10.1136\/openhrt-2022-002184.","journal-title":"Open Heart"},{"issue":"5","key":"438_CR28","doi-asserted-by":"publisher","first-page":"e809","DOI":"10.1016\/j.jacl.2024.05.003","volume":"18","author":"I Naoum","year":"2024","unstructured":"Naoum I, Saliba W, Aker A, Zafrir B. Lipid-lowering therapy with inclisiran in the real-world setting: initial data from a national health care service. J Clin Lipidol. 2024;18(5):e809\u201316. https:\/\/doi.org\/10.1016\/j.jacl.2024.05.003.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"438_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8\u201327. https:\/\/doi.org\/10.1097\/00005650-199801000-00004.","journal-title":"Med Care"},{"issue":"Suppl. 1","key":"438_CR30","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","volume":"13","author":"S Cuschieri","year":"2019","unstructured":"Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13(Suppl. 1):S31\u20134. https:\/\/doi.org\/10.4103\/sja.SJA_543_18.","journal-title":"Saudi J Anaesth"},{"issue":"34","key":"438_CR31","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","volume":"43","author":"I Byty\u00e7i","year":"2022","unstructured":"Byty\u00e7i I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43(34):3213\u201323. https:\/\/doi.org\/10.1093\/eurheartj\/ehac015.","journal-title":"Eur Heart J"},{"issue":"7","key":"438_CR32","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011765","volume":"8","author":"CK Bradley","year":"2019","unstructured":"Bradley CK, Wang TY, Li S, et al. Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM registry. J Am Heart Assoc. 2019;8(7):e011765. https:\/\/doi.org\/10.1161\/JAHA.118.011765.","journal-title":"J Am Heart Assoc"},{"key":"438_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/PPA.S502645","volume":"19","author":"J Rosenberg","year":"2025","unstructured":"Rosenberg J, Lampridou S, Moores A, Garfield S, Wingfield D, Judah G. A systematic review uncovering modifiable influences on statin adherence. Patient Prefer Adher. 2025;19:29\u201348. https:\/\/doi.org\/10.2147\/PPA.S502645.","journal-title":"Patient Prefer Adher"},{"issue":"24","key":"438_CR34","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168\u2013209. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.002.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"438_CR35","doi-asserted-by":"publisher","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","volume":"158","author":"H Zhang","year":"2013","unstructured":"Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158(7):526\u201334. https:\/\/doi.org\/10.7326\/0003-4819-158-7-201304020-00004.","journal-title":"Ann Intern Med"},{"key":"438_CR36","doi-asserted-by":"publisher","first-page":"215013192412363","DOI":"10.1177\/21501319241236339","volume":"15","author":"CN Deaney","year":"2024","unstructured":"Deaney CN, Donaldson MP, Reesby DM, et al. Retrospective evaluation of LDL-C levels following first treatment with inclisiran as part of secondary prevention ASCVD risk reduction in a real-world primary care setting. J Prim Care Community Health. 2024;15:21501319241236340. https:\/\/doi.org\/10.1177\/21501319241236339.","journal-title":"J Prim Care Community Health"},{"issue":"Suppl. 2","key":"438_CR37","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad655.2812","volume":"44","author":"C Basile","year":"2023","unstructured":"Basile C, Gargiulo P, Merlini PA, et al. Efficacy and safety of inclisiran in real world practice: insights from the Cholinet registry. Eur Heart J. 2023;44(Suppl. 2):ehad655.2812. https:\/\/doi.org\/10.1093\/eurheartj\/ehad655.2812.","journal-title":"Eur Heart J"},{"issue":"3","key":"438_CR38","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.clinthera.2023.12.003","volume":"46","author":"S Iqbal","year":"2024","unstructured":"Iqbal S, Sabbour HM, Ashraf T, Santos RD, Buckley A. First report of inclisiran utilization for hypercholesterolemia treatment in real-world clinical settings in a Middle East population. Clin Ther. 2024;46(3):186\u201393. https:\/\/doi.org\/10.1016\/j.clinthera.2023.12.003.","journal-title":"Clin Ther"},{"issue":"11","key":"438_CR39","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028892","volume":"12","author":"MJ Wilkinson","year":"2023","unstructured":"Wilkinson MJ, Lepor NE, Michos ED. Evolving management of low-density lipoprotein cholesterol: a personalized approach to preventing atherosclerotic cardiovascular disease across the risk continuum. J Am Heart Assoc. 2023;12(11):e028892. https:\/\/doi.org\/10.1161\/JAHA.122.028892.","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"438_CR40","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s00392-023-02247-8","volume":"112","author":"U Makhmudova","year":"2023","unstructured":"Makhmudova U, Schatz U, Perakakis N, et al. High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany. Clin Res Cardiol. 2023;112(11):1639\u201349. https:\/\/doi.org\/10.1007\/s00392-023-02247-8.","journal-title":"Clin Res Cardiol"},{"issue":"6","key":"438_CR41","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1007\/s00392-023-02257-6","volume":"113","author":"W Koenig","year":"2024","unstructured":"Koenig W, Lorenz ES, Beier L, Gouni-Berthold I. Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany. Clin Res Cardiol. 2024;113(6):812\u201321. https:\/\/doi.org\/10.1007\/s00392-023-02257-6.","journal-title":"Clin Res Cardiol"},{"issue":"18 Suppl. 1","key":"438_CR42","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/s0735-1097(21)02939-9","volume":"77","author":"R Lahoz","year":"2021","unstructured":"Lahoz R, Seshagiri D, Achouba A, et al. Treatment patterns in atherosclerotic cardiovascular disease patients with hypercholesterolemia (ASCVD-H) and patients with familial hypercholesterolemia (FH), a retrospective database cohort study in the US. J Am Coll Cardiol. 2021;77(18 Suppl. 1):1582. https:\/\/doi.org\/10.1016\/s0735-1097(21)02939-9.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"438_CR43","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.118.005404","volume":"12","author":"KD Myers","year":"2019","unstructured":"Myers KD, Farboodi N, Mwamburi M, et al. Effect of access to prescribed PCSK9 inhibitors on cardiovascular outcomes. Circ Cardiovasc Qual Outcomes. 2019;12(8):e005404. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.118.005404.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"438_CR44","doi-asserted-by":"publisher","first-page":"8129513","DOI":"10.1155\/2022\/8129513","volume":"2022","author":"I Mer\u0107ep","year":"2022","unstructured":"Mer\u0107ep I, Fri\u0161\u010di\u0107 N, Striki\u0107 D, Reiner \u017d. Advantages and disadvantages of inclisiran: a small interfering ribonucleic acid molecule targeting PCSK9\u2014a narrative review. Cardiovasc Ther. 2022;2022:8129513. https:\/\/doi.org\/10.1155\/2022\/8129513.","journal-title":"Cardiovasc Ther"},{"issue":"12","key":"438_CR45","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","volume":"120","author":"RS Wright","year":"2024","unstructured":"Wright RS, Raal FJ, Koenig W, et al. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovasc Res. 2024;120(12):1400\u201310. https:\/\/doi.org\/10.1093\/cvr\/cvae109.","journal-title":"Cardiovasc Res"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00438-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-025-00438-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00438-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:14:32Z","timestamp":1764951272000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-025-00438-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["438"],"URL":"https:\/\/doi.org\/10.1007\/s40119-025-00438-0","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Christie M. Ballantyne has received grant\/research support (through his institution) from Abbott Diagnostics, Akcea, Amgen, Arrowhead, Ionis, Merck, New Amsterdam, Novartis, Novo Nordisk, and Roche Diagnostics; and consulting fees from 89bio, Abbott Diagnostics, Amarin, Amgen, Arrowhead, AstraZeneca, Denka Seiken, Esperion, Genentech, Illumina, Ionis, Eli Lilly, Merck, New Amsterdam, Novartis, Novo Nordisk, and Roche Diagnostics. Lucinda J. Van Anglen has received grant\/research support from Novartis. Xiaoli Niu is an employee and stockholder of Novartis. Sean McElligott is an employee of Novartis and a stockholder of Novartis, Johnson and Johnson, and Merck. Tyler J. Varisco is a consultant with Healix Infusion Therapy, LLC. Tyler J. Varisco is now affiliated with the University of Texas at Austin College of Pharmacy, TX, USA. Timothy E. Graham, Bruce J. Iteld, Harvey Serota, and Kelly E. Hanna have no disclosures to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures were approved by Biomedical Research Alliance of New York, an independent institutional review board (#22-12-927-1297). As this was a secondary analysis of data collected in the provision of care, the study was deemed exempt from human subject restrictions. No participant identifiers were used in the analysis and patients were not required to provide consent for inclusion. Data collection was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and is consistent with the Guidelines for Good Clinical Practice. Reporting followed the Strengthening the Reporting of Observational studies in Epidemiology\u00a0(STROBE) Guideline for Cohort Studies [\n                      \n                      ].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}